Investigating new treatment targets for diffuse large B cell lymphoma
Official title: From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
Funded at Columbia University Health Sciences · NIH-10928175 · Data updated 2026-11-12
This study is looking at a tough type of cancer called diffuse large B cell lymphoma (DLBCL) to find new ways to treat it by exploring the genes that might be causing the cancer to behave differently, and it’s for patients who are facing challenges with their current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 12, 2023 |
| Project end | July 31, 2030 |
| Funding year | 2024 |
| Award (this year) | $937,650 |
| NIH project number | 5R35CA210105-09 |
| Project ID | NIH-10928175 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B cell lymphoma, particularly those who have not responded to current therapies.
✕Less likely to help
Patients with other types of lymphoma or those who are not diagnosed with diffuse large B cell lymphoma may not benefit from this research.
What this research studies
This research focuses on diffuse large B cell lymphoma (DLBCL), a type of cancer that is difficult to treat and remains incurable for about 30% of patients. The study aims to uncover new therapeutic targets by exploring the genetic complexity of DLBCL, particularly in non-coding regions of the genome that may harbor mutations affecting tumor behavior. By utilizing advanced techniques like CRISPR, the researchers will analyze regulatory elements in the genome to identify potential new treatment strategies. This could lead to more effective therapies tailored to the unique genetic makeup of each patient's cancer.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and personalized treatments for patients with diffuse large B cell lymphoma.
How similar studies have gone: Other research has shown promise in targeting genetic mutations in cancers, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Dalla-Favera, Riccardo — Columbia University Health Sciences
- Study coordinator: Dalla-Favera, Riccardo
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.